OBJECTIVES: To report anatomic and functional outcomes 2 years after sacrocolpopexy in stress-continent women with or without prophylactic Burch colposuspension. METHODS: In the Colpopexy and Urinary Reduction Efforts (CARE) trial, stress-continent women undergoing sacrocolpopexy were randomized to receive or not receive a Burch colposuspension. Outcomes included urinary symptoms, other pelvic symptoms, and pelvic support. Standardized pelvic organ prolapse quantification examinations and validated outcome measures including the Pelvic Floor Distress Inventory and the Pelvic Floor Impact Questionnaire were completed before surgery and at several postoperative intervals, including at 2 years. RESULTS: This analysis is based on 322 randomized participants; certain analyses were done with a subset based on data availability. Most were Caucasian (94%), with a mean age of 62±10 years (mean±standard deviation). Two years after surgery, 41.8% and 57.9% of women in the Burch and control groups, respectively, met the stress incontinence endpoint (presence of symptoms or positive cough stress test or interval treatment for stress incontinence, P=.020). The apex was well supported (point C within 2 cm of total vaginal length) in 95% of women, and this was not affected by concomitant Burch (P=.18). There was a trend toward fewer urgency symptoms in the Burch group (32.0% versus 44.5% no Burch, P=.085). Twenty participants experienced mesh or suture erosions. CONCLUSION: The early advantage of prophylactic Burch colposuspension for stress incontinence that was seen at 3 months remains at 2 years. Apical anatomic success rates are high and not affected by concomitant Burch. CLINICAL TRIAL REGISTRATION: (www.clinicaltrials.gov), ClinicalTrials.gov, NCT00065845. LEVEL OF EVIDENCE: I.
RCT Entities:
OBJECTIVES: To report anatomic and functional outcomes 2 years after sacrocolpopexy in stress-continent women with or without prophylactic Burch colposuspension. METHODS: In the Colpopexy and Urinary Reduction Efforts (CARE) trial, stress-continent women undergoing sacrocolpopexy were randomized to receive or not receive a Burch colposuspension. Outcomes included urinary symptoms, other pelvic symptoms, and pelvic support. Standardized pelvic organ prolapse quantification examinations and validated outcome measures including the Pelvic Floor Distress Inventory and the Pelvic Floor Impact Questionnaire were completed before surgery and at several postoperative intervals, including at 2 years. RESULTS: This analysis is based on 322 randomized participants; certain analyses were done with a subset based on data availability. Most were Caucasian (94%), with a mean age of 62±10 years (mean±standard deviation). Two years after surgery, 41.8% and 57.9% of women in the Burch and control groups, respectively, met the stress incontinence endpoint (presence of symptoms or positive cough stress test or interval treatment for stress incontinence, P=.020). The apex was well supported (point C within 2 cm of total vaginal length) in 95% of women, and this was not affected by concomitant Burch (P=.18). There was a trend toward fewer urgency symptoms in the Burch group (32.0% versus 44.5% no Burch, P=.085). Twenty participants experienced mesh or suture erosions. CONCLUSION: The early advantage of prophylactic Burch colposuspension for stress incontinence that was seen at 3 months remains at 2 years. Apical anatomic success rates are high and not affected by concomitant Burch. CLINICAL TRIAL REGISTRATION: (www.clinicaltrials.gov), ClinicalTrials.gov, NCT00065845. LEVEL OF EVIDENCE: I.
Authors: P Antiphon; S Elard; A Benyoussef; M Fofana; R Yiou; M Gettman; A Hoznek; D Vordos; D K Chopin; C C Abbou Journal: Eur Urol Date: 2004-05 Impact factor: 20.096
Authors: Pierre Gadonneix; Alfredo Ercoli; Delphine Salet-Lizée; Odile Cotelle; Brigitte Bolner; Michel Van Den Akker; Richard Villet Journal: J Am Assoc Gynecol Laparosc Date: 2004-02
Authors: Linda Brubaker; Geoff Cundiff; Paul Fine; Ingrid Nygaard; Holly Richter; Anthony Visco; Halina Zyczynski; Morton B Brown; Anne Weber Journal: Control Clin Trials Date: 2003-10
Authors: Ingrid E Nygaard; Rebecca McCreery; Linda Brubaker; AnnaMarie Connolly; Geoff Cundiff; Anne M Weber; Halina Zyczynski Journal: Obstet Gynecol Date: 2004-10 Impact factor: 7.661
Authors: Miles Murphy; Adam Holzberg; Heather van Raalte; Neeraj Kohli; Howard B Goldman; Vincent Lucente Journal: Int Urogynecol J Date: 2011-11-16 Impact factor: 2.894
Authors: Linda Brubaker; Matthew D Barber; Ingrid Nygaard; Charlie W Nager; Edward Varner; Joseph Schaffer; Anthony Visco; Susan Meikle; Cathie Spino Journal: Am J Obstet Gynecol Date: 2010-08-21 Impact factor: 8.661
Authors: Manhan K Vu; Juraj Letko; Kelly Jirschele; Adam Gafni-Kane; Aimee Nguyen; Honyan Du; Roger P Goldberg Journal: Int Urogynecol J Date: 2012-04-25 Impact factor: 2.894
Authors: Holly E Richter; Kathryn L Burgio; Toby C Chai; Stephen R Kraus; Yan Xu; Lee Nyberg; Linda Brubaker Journal: Int Urogynecol J Pelvic Floor Dysfunct Date: 2009-01-30